Cerebrovascular diseases: perspectives of pathogenetic metabolic correction treatment

Author:
M.M. TANASHYAN, O.V. LAGODA, K.V. ANTONOVA
Research Centre of Neurology, Moscow, Russia

Summary:
Metabolic syndrome is a serious risk factor for acute and chronic cerebrovascular disease, which are a leading cause of disabling conditions. The association of proatherogenic effects of the main components of metabolic syndrome – hyperinsulinemia, arterial hypertension, dyslipidemia and obesity – leads to prominent haemorheological and hemostasis changes, which in turn play a pivotal role in the initiation, course and outcome of cerebrovascular pathology. Metabolic syndrome also influences the efficacy of the main pathogenetic therapy of cerebrovascular diseases — antithrombotic therapy. Thus, primary and secondary prevention of cerebrovascular disease in patients with metabolic syndrome should include haemangiocorrective, antithrombotic, antioxidant and endothelium-protective treatment, as well as therapy of the main components of metabolic syndrome.

Keywords: cerebrovascular disease, metabolic syndrome, haemorheology and haemostasis, antithrombotic therapy, antioxidants.